Abstract: Patients who successfully complete treatment for prostate cancer face an almost 33% chance of disease recurrence in the next 10 to 15 years, during which the positioning of the lesion and its development stage should be precisely identified using PET/CT.PET imaging agents that are currently used to diagnose PCa are ¹⁸F-FDG, ¹¹C-choline, ¹⁸F-choline, and ⁶⁸Ga-prostate-specific membrane antigen (⁶⁸Ga-PSMA).However, the diagnosis of PCa is insufficient due to the poor intake of ¹⁸F-FDG in PCa cells and the short half-life of ¹¹C-choline.¹⁸F-fluorocyclobutane carboxylic acid (¹⁸F-FACBC) has the advantages of strong specificity of PCa cells, long half-life, and simple preparation requirements and can therefore be an imaging agent for PCa diagnosis.